Genemedi produces core diagnostic ingredients for test of Fertility (premature?delivery) and related syndrome. GeneMedi offers paired diagnostics grade Fetal fibronectin (fFN) antibodies (monoclonal antibody, mab) and antigens for Fertility (premature?delivery) rapid test kit of Fetal fibronectin (fFN) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Fertility (premature?delivery ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Fetal fibronectin (fFN) is a protein produced at the boundary between the amniotic sac (which surrounds the baby) and the lining of the mother’s uterus (the decidua). Fetal fibronectin is largely confined to this junction and is thought to help “glue” or maintain the integrity of the boundary between the amniotic sac and the lining of the uterus. A fetal fibronectin test detects fFN in vaginal fluid to help predict the short-term risk of premature delivery. According to the American College of Obstetricians and Gynecologists (ACOG), a normal pregnancy is about 40 weeks, with a woman going into labor between 37 and 42 weeks. A preterm delivery is one that occurs between 20 and 37 weeks of pregnancy. fFN is found in vaginal fluids early in pregnancy because of the normal growth and establishment of tissues at the junction between the amniotic sac and uterus, with levels falling when this phase is complete. fFN is also found in fluids from the vagina after 36 weeks when it is often released into vaginal fluids as the body gets ready for childbirth. However, fFN should not be detectible between 22 and 35 weeks of pregnancy. Elevated levels during this period reflect a disturbance at the junction between the amniotic sac and the lining of the uterus. Elevated fFN in vaginal fluids during these weeks of pregnancy has been associated with an increased risk of preterm labor and delivery. Many pregnant women experience symptoms that suggest preterm labor. These may include uterine contractions, changes in vaginal discharge, backaches, abdominal discomfort, pelvic pressure, cramping, and dilation of the cervix. However, not all symptomatic women will actually have a preterm delivery. The majority will go on to deliver at term. Unfortunately, while premature births can have successful endings, serious complications are possible when a baby leaves the womb early. Premature babies frequently have difficulty breathing and feeding. Their lungs and other organs are immature and do not function normally, and the strain on them can cause persistent health problems. The more premature the newborn, the more likely it is that he or she will experience complications. If a healthcare practitioner thinks that a woman might deliver early, she will consider treatments designed to delay delivery. These treatments can have unwanted side effects, however, so knowing whether or not a woman is likely to deliver prematurely helps in the decision on the best course of action. The fFN test is a relatively noninvasive tool that can help distinguish between those women who are likely to deliver shortly and those who are not.